International Ledless Pacemaker Registry

NCT05528029 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2022-12-23

No results posted yet for this study

Summary

The Micra MC1VR01 or Micra AVMC1AVR1 Transcatheter Pacing System (Medtronic, Inc., Minneapolis, MN, USA) has become a major breakthrough as an alternative to standard transvenous pacemakers.

The aim of this multi-center study is to assess the clinical outcomes of patients implanted with Micra LLPM in real life, in different clinical scenarios.

Conditions

Interventions

DEVICE

Leadless Pacemaker (Micra)

Micra leadless pacemaker is implanted in the right ventricle via femoral vein. The Micra introducer/dilator assembled system is inserted over a stiff guidewire in the right atrium. After the removal of the guidewire and the dilator, the delivery system is advanced into the introducer and the Micra is placed under fluoroscopy guidance, preferably in the septal region of the right ventricle.

Sponsors & Collaborators

  • Università degli Studi di Brescia

    collaborator OTHER
  • Centro Cardiologico Monzino

    collaborator OTHER
  • University Hospital, Zürich

    collaborator OTHER
  • Azienda Ospedaliera Cardinale G. Panico

    collaborator OTHER
  • Azienda Ospedaliera San Gerardo di Monza

    collaborator OTHER
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    collaborator OTHER
  • San Raffaele University Hospital, Italy

    collaborator OTHER
  • Ospedale V. Fazzi

    collaborator OTHER
  • Ospedali Riuniti Ancona

    collaborator OTHER
  • Universitair Ziekenhuis Brussel

    collaborator OTHER
  • Università degli Studi di Ferrara

    collaborator OTHER
  • University of Padova

    collaborator OTHER
  • Luigi Sacco University Hospital

    lead OTHER

Principal Investigators

  • Giovanni B Forleo, MD, PhD · Luigi Sacco University Hospital

  • Gianfranco MItacchione, MD, PhD · Luigi Sacco University Hospital

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2024-12-31
Completion
2024-12-31
FDA Device
Yes

Countries

  • Belgium
  • Italy
  • Switzerland

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05528029 on ClinicalTrials.gov